Drug Trial Radar · NCT00131638
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer
Last checked: Nov 20, 2026Latest source record: Dec 16, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
241
Actual
Start
Jan 2005
Primary completion
Nov 2007
Study completion Jul 2016
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Aug 19, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of palifermin (recombinant human keratinocyte growth factor, rHuKGF) in reducing the incidence of severe oral mucositis in subjects with locally advanced head and neck cancer receiving radiotherapy with concurrent chemotherapy as adjuvant treatment for their disease.
Conditions
- Head and Neck Cancer
Interventions
PlaceboDrug
Single IV dose of placebo at 120 μg/kg, 3 days before the start of Radiotherapy, plus 6 once weekly placebo doses at the same dose during a 6-week radiotherapy / chemotherapy course.
PaliferminDrug
Single IV dose of palifermin at 120 μg/kg, 3 days before the start of radiotherapy plus 6 once weekly palifermin doses at the same dose level during a 6-week Radiotherapy / chemotherapy course
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence percentage of severe oral mucositis (Grades 3 or 4 on the WHO oral mucositis scale)Time frame: Up to 24 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.